Biotech Proposes Paying for Pricey Drugs by Installment

0
1

A Boston-area biotech says it might have a found a approach to hoop a approaching seven-figure cost of the initial gene therapy: profitable on installment.

Bluebird Bio Inc. is building skeleton to sell the initial gene-replacement therapy, for a singular hereditary blood disease, on a five-year installment plan, with any annual remuneration fortuitous on the treatment’s continued effectiveness.

Bluebird,…

LEAVE A REPLY

Please enter your comment!
Please enter your name here